News | October 01, 2013

Siemens Receives 2013 North American Frost & Sullivan Award for Company of the Year

Siemens, Siemens logo, Siemens Healthcare

October 1, 2013 — Based on its recent analysis of the molecular imaging market, Frost & Sullivan recognizes Siemens Healthcare with the 2013 North American Frost & Sullivan Award for Company of the Year. Siemens Healthcare has dedicated equal attention and resources to the development of both single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging – the two pillars of molecular imaging. The company has moved quickly to innovate and strategize in a rapidly evolving market to secure for itself an ideal market position.

Siemens Healthcare has made breakthrough technological innovations in the SPECT market, but what is truly impressive is that it accomplished this in a rather saturated, low-turnover market for new equipment purchases. It has made similar advances in PET imaging, and has been at the forefront of the most promising clinical applications in oncology, neurology, and cardiology.

As new PET radiopharmaceutical agents for use in the evaluation of Alzheimer's and other cognitive diseases gain approval by the U.S. Food and Drug Administration (FDA), Siemens Healthcare’s early efforts have allowed the company to promptly design and deliver the industry’s first end-to-end amyloid PET imaging solution. By combining the equipment and software advances of the new syngo.PET amyloid plaque solution with the reliable manufacturing and distribution network of Siemens’ PETNET Solutions, Siemens has become the PET solution provider of choice in neurology.

“Having recognized many years ago that the future of medical imaging would hinge on more advanced and efficient hybrid imaging modalities, Siemens Healthcare has built a legacy of industry firsts,” said Frost & Sullivan Industry Principal Nadim Michel Daher. “Today, as the result of this continuous technology and product advancement, Siemens Healthcare is leading the way in the imaging industry with regard to each of the SPECT/CT, PET/CT and PET/MR imaging modalities.”

In PET/CT imaging, the enhanced capabilities and image resolution of the new Biograph mCT Flow now enable physicians to rely on molecular imaging with accurate and reproducible quantification. Siemens’s groundbreaking FlowMotion technology, which goes beyond the traditional stop-and-go image acquisition technique by offering a continuous flow motion of the patient table, is yet another technological enabler. Similarly, in SPECT/CT, the xSPECT technology-based Symbia Intevo empowers nuclear medicine and is a game-changer. xSPECT is a novel reconstruction technique that extends beyond attenuation correction to use voxel-based registration of both the SPECT and CT datasets.

“The ongoing cycles of product and technology innovation within each sub-specialty field allow Siemens’s current and prospective customers to make more collaborative equipment purchases,” noted Daher. “This multi-specialty approach to imaging might still be an emerging best practice used by avant-garde providers today, but it is slated to become the new standard of care for providers. Siemens’ molecular imaging customers will be better equipped during this reshaping of the clinical and business models for molecular imaging.”

In addition to its leadership in the premium-tier product segments, Siemens Healthcare also has polished its entry-level offerings to cater to the mid-tier and value-based customer segments. The company continues to make its molecular imaging product portfolio more modular, enabling a more cost-effective and phased adoption of high-end technology by various types of providers.

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in terms of growth strategy and implementation. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.

For more information: www.frost.com

Related Content

Toshiba Showcases MRI Workflow Enhancements at RSNA 2017
News | Magnetic Resonance Imaging (MRI) | September 21, 2017
September 21, 2017 — Toshiba Medical will highlight its latest...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Study Assesses Usefulness of MRI for Pediatric Sports-Related Concussion
News | Neuro Imaging | September 05, 2017
September 5, 2017 — A new study reviewed more than 5 years of records of...
Overlay Init